Elsalys Biotech SAS-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Elsalys Biotech SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014294
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Elsalys Biotech SAS (Elsalys Biotech) is a biotechnology company that designs and develops therapeutic antibodies in oncology and ophthalmology. The company’s pipeline products include monoclonal antibodies designed to fight against cancers, vascular eye, idiopathic pulmonary fibrosis and chronic obstructive pulmonary diseases. Its specialization spans from target sourcing to the pre-industrial production of drug candidates. It works in collaboration with academic and other industry partners to conduct programs, clinical evaluation of antibody candidates and to develop immune-based therapies. The company owns and operates laboratories located in the Illkirch Graffenstaden Science and Technology Park. Elsalys Biotech is headquartered in Lyon, France.

Elsalys Biotech SAS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Elsalys Biotech SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Elsalys Biotech SAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Elsalys Biotech SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Elsalys Biotech SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Elsalys Biotech SAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Elsalys Biotech SAS, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 10
ElsaLys Biotech Acquires Rights of Anti-CD160 Antibody from MabLife 11
Venture Financing 12
ElsaLys Biotech Raises Additional USD3 Million in Financing Round 12
ElsaLys Biotech Raises US$2.7 Million In First Round Of Financing 13
Licensing Agreements 14
Elsalys Biotech Enters into Licensing Agreement with Transgene 14
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 15
Elsalys Biotech SAS – Key Competitors 16
Elsalys Biotech SAS – Key Employees 17
Elsalys Biotech SAS – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Corporate Communications 19
Jan 30, 2017: Elsalys Biotech expands its team to strengthen its strategy and the development of its programs 19
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Elsalys Biotech SAS, Pharmaceuticals & Healthcare, Key Facts 2
Elsalys Biotech SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Elsalys Biotech SAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Elsalys Biotech SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Elsalys Biotech SAS, Deals By Therapy Area, 2011 to YTD 2017 8
Elsalys Biotech SAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 10
ElsaLys Biotech Acquires Rights of Anti-CD160 Antibody from MabLife 11
ElsaLys Biotech Raises Additional USD3 Million in Financing Round 12
ElsaLys Biotech Raises US$2.7 Million In First Round Of Financing 13
Elsalys Biotech Enters into Licensing Agreement with Transgene 14
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 15
Elsalys Biotech SAS, Key Competitors 16
Elsalys Biotech SAS, Key Employees 17
Elsalys Biotech SAS, Other Locations 18

★海外企業調査レポート[Elsalys Biotech SAS-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Reckitt Benckiser Group Plc (RB.):企業の財務・戦略的SWOT分析
    Reckitt Benckiser Group Plc (RB.) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Taylor Wessing Llp
    Taylor Wessing Llp - Strategy, SWOT and Corporate Finance Report Summary Taylor Wessing Llp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Akenerji Elektrik Uretim AS (AKENR):企業の財務・戦略的SWOT分析
    Akenerji Elektrik Uretim AS (AKENR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • MAEC-Kazatomprom LLP:企業の戦略的SWOT分析
    MAEC-Kazatomprom LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Balfour Beatty plc:企業の戦略・SWOT・財務情報
    Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report Summary Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Strategic Oil & Gas Ltd (SOG):企業の財務・戦略的SWOT分析
    Summary Strategic Oil & Gas Ltd (Strategic Oil & Gas) is an upstream oil and gas exploration and development company. The company acquires, explores, operates, manages, and develops crude oil and natural gas assets. It holds interests and operates its oil and gas exploration projects such as Marlowe …
  • Splendid Metal Products Limited:企業の戦略・SWOT・財務情報
    Splendid Metal Products Limited - Strategy, SWOT and Corporate Finance Report Summary Splendid Metal Products Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Federal-Mogul Holdings LLC:企業の戦略的SWOT分析
    Federal-Mogul Holdings LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Intercept Pharmaceuticals Inc (ICPT):製薬・医療:M&Aディール及び事業提携情報
    Summary Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops and commercializes treatments for non-viral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid ( …
  • CHC Group Ltd (HELIQ)-石油・ガス分野:企業M&A・提携分析
    Summary CHC Group Ltd. (CHC) is a commercial operator of medium and heavy helicopters that provides mission-critical services, search and rescue services, emergency and medical services, maintenance repair and overhauling services, helicopter parts sales and distribution, integrated logistics suppor …
  • Builders FirstSource Inc:戦略・SWOT・企業財務分析
    Builders FirstSource Inc - Strategy, SWOT and Corporate Finance Report Summary Builders FirstSource Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Pulsion Medical Systems SE (PUS):医療機器:M&Aディール及び事業提携情報
    Summary Pulsion Medical Systems SE (Pulsion Medical Systems), formerly Pulsion Medical Systems AG, a subsidiary of Getinge AB, is a medical device company that manufactures and develops critical care systems and monitors. The company’s products include ProAQT sensor, PiCCO catheter, CeVOX module, Pi …
  • Croma-Pharma GmbH-医療機器分野:企業M&A・提携分析
    Summary Croma-Pharma GmbH (Croma Pharma) is a pharmaceutical company which focuses on the development and commercialization of drugs in the field of aesthetic dermatology. It offers princess injectables, princess skincare, and princess lift products. The company’s princess skincare products comprise …
  • Service Corporation International (SCI):企業の財務・戦略的SWOT分析
    Service Corporation International (SCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • International Flavors & Fragrances Inc (IFF):企業の財務・戦略的SWOT分析
    International Flavors & Fragrances Inc (IFF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Tecpetrol S.A.:企業の戦略・SWOT・財務分析
    Tecpetrol S.A. - Strategy, SWOT and Corporate Finance Report Summary Tecpetrol S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Heinzel Holding GmbH:企業の戦略的SWOT分析
    Heinzel Holding GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Beach Energy Ltd (BPT):石油・ガス:M&Aディール及び事業提携情報
    Summary Beach Energy Ltd (Beach Energy) is an independent upstream oil and gas company. It carries out the exploration, development, production, transportation and marketing of oil and natural gas. The company has core exploration and development drilling operations in the Cooper and Eromanga basins …
  • Bank Leumi le-Israel B.M.:戦略・SWOT・企業財務分析
    Bank Leumi le-Israel B.M. - Strategy, SWOT and Corporate Finance Report Summary Bank Leumi le-Israel B.M. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Southern Co (SO):企業の財務・戦略的SWOT分析
    Southern Co (SO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆